Why in News?                                                                                                        

In a breakthrough towards enhancing the quality of life for cancer patients undergoing radiotherapy, scientists from Department of Atomic Energy and M/s. IDRS Labs Pvt. Ltd. Bengaluru have joined hands to develop AKTOCYTE tablets. Experts from Bhabha Atomic Research Centre, Mumbai; Tata Memorial Hospital, Mumbai; Advanced Centre for Training Research and Education in Cancer, Navi Mumbai collaborated with the IDRS Labs with a primary aim of minimizing the side effects of radiotherapy.

What is Aktocyte?

  • The AKTOCYTE tablets have shown remarkable results, particularly in pelvic cancer patients suffering from radiotherapy-induced Cystitis (Blood in urine).
  • Patients treated with AKTOCYTE tablets demonstrated an extraordinary recovery, eliminating the need for surgical removal of the urinary bladder.
  • The tablets, designed as an adjuvant to cancer radiotherapy, regenerative nutraceutical, immunomodulator, and antioxidant, mark a significant advancement in cancer care.
  • AKTOCYTE has received approval from the Food Safety and Standards Authority of India (FSSAI), operating under the Ministry of Health & Family Welfare, Government of India.
  • Anticipated to hit the market in January 2024, AKTOCYTE tablets are poised to become a transformative addition to cancer treatment protocols.